Mohamed El Fakiri, Nawal Ayada, Marius Müller, Lars Hvass, Teodor H Gamzov, Anne Skovsbo Clausen, Nicolas M Geis, Nils Steinacker, Ellinor Hansson, Sture Lindegren, Emma Aneheim, Holger Jensen, Ann-Christin Eder, Andreas I Jensen, Christian B M Poulie, Andreas Kjaer, Matthias Eder, Matthias M Herth
The application of prostate-specific membrane antigen (PSMA)-targeted α-therapy is a promising alternative to β- -particle-based treatments. 211 At is among the potential α-emitters that are favorable for this concept. Herein, 211 At-based PSMA radiopharmaceuticals were designed, developed, and evaluated. Methods: To identify a 211 At-labeled lead, a surrogate strategy was applied. Because astatine does not exist as a stable nuclide, it is commonly replaced with iodine to mimic the pharmacokinetic behavior of the corresponding 211 At-labeled compounds...
February 29, 2024: Journal of Nuclear Medicine